The chart below shows how QTRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, QTRX sees a +1.76% change in stock price 10 days leading up to the earnings, and a +3.01% change 10 days following the report. On the earnings day itself, the stock moves by -0.72%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Revenue Increase Q3 2024: Q3 2024 total revenue reached $35.7 million, marking a 13% increase compared to the prior year.
Accelerator Lab Revenue Surge: Accelerator lab revenue grew to $10.5 million, reflecting a 36% increase driven by strong demand for clinical trial services.
Consumables Revenue Increase: Consumables revenue increased by 8% to $17.3 million, offsetting a decline in instrument revenue, which was $2.4 million, a decrease of 39%.
Gross Profit Increase: The third quarter non-GAAP gross profit was $21.1 million, up $2.2 million from the prior year, with a gross margin of 58.9%.
Product Commercialization Update: Year-to-date, the company has commercialized a total of 16 new products, including several novel multiplexes, with plans to launch another four assays by the end of the year.
Negative
Quarterly Revenue Analysis: Total revenue for the third quarter of 2024 was $35.7 million, an increase of 13% compared to the prior year, but the instrument revenue was $2.4 million, a decrease of 39%.
Gross Profit and Margin Analysis: The third quarter preliminary non-GAAP gross profit was $19.1 million, and preliminary non-GAAP gross margin was 53.4%, up $2.8 million, but approximately 160 basis points lower compared to the third quarter of 2023.
Cash Flow Challenges: Cash flow in the period was a net outflow of $3.3 million, which was higher than the prior year period by $1.5 million, indicating cash management challenges.
Regional Market Performance: The Europe region grew only 2%, while the Asia-Pacific region was down 34% in the period, reflecting regional market difficulties.
Financial Reporting Restatement Issues: The company disclosed the need to restate certain prior period financial statements to correct non-cash errors related to those periods, indicating potential issues with financial reporting integrity.
Quanterix Corporation (QTRX) Q3 2024 Earnings Conference Call Transcript
QTRX.O
3.19%